Introduction
Inhibin is classically defined as a non-steroidal hormone produced by the gonads, which has an inhibitory effect upon the secretion of follicle-stimulating hormone (FSH) by the pituitary. The concept of an 'inhibin' was postulated some 70 years ago (McCullagh, 1932) , but the biological entity, a glycoprotein hormone, was first isolated from bovine follicular fluid and characterized in 1985 (Robertson et al., 1985) . The cloning of the complementary DNA and the full structure of the bovine and human molecules was achieved shortly afterwards (Forage et ai, 1986; Mason et al., 1986; Stewart et al., 1987) . It is known that inhibin is a heterodimer consisting of and ß subunits and has structural homology to other bioactive glycoproteins, including Müllerian Inhibitory Substance, transforming growth factor ß, activin, erythroid-differentiating factor and bone morphogenic proteins, suggesting that inhibin has paracrine or autocrine as well as endocrine function (for reviews, see de Jong et al., 1990; Ling et al., 1990) .
The physiological endocrine role of inhibin in the male and female of various species, including man, has been a subject of active research, although in vivo experimental studies, including those on the potential use of inhibin as a male antifertility agent, have been hampered by the lack of supplies of inhibin.
Throughout the past 20 years, studies on inhibin-like bioactivity isolated from tissue such as testis, ovary, placenta (or, more (Bethesda, MD) arranged to provide a sufficient quantity of an extract of porcine follicular fluid and the first research standard for porcine inhibin was ampouled at the National Institute for Biological Standards and Control (NIBSC) in 1986. Provisional assessment of this research standard, ampoule code 86/690, was carried out as described elsewhere (Waites et ai, 1987) and the material was made available on an international basis for research in 1987.
The international collaborative study reported here was initiated in 1988 to assess the stability and suitability of the WHO/NIH research standard of partially purified porcine ovarian follicular fluid inhibin (code 86/690) to serve as an International Standard and to compare it with ampouled samples of inhibins from bovine and human follicular fluid and with ovine rete testes fluid, which were representative of a wide variety of working standards used in various bioassay systems in vitro. It was hoped that the information obtained from the study would also permit an independent assessment of the variability of the in vitro bioassay systems in widest use for inhibins.
Materials and Methods

First International Standard for Porcine Inhibin
Bulk material for 86/690. The bulk material consisted of 40 mg of an extract of porcine follicular fluid, batch number WLG-4-55B, which had been prepared by procedures similar to those described by Gordon et al. (1986) . The inhibin was partially purified from charcoal-treated porcine follicular fluid by precipitation with acetone and by chromatography on Sephacryl S200 and Sephadex G75. The inhibin potency of WLG-4-55B was assessed in an in vitro rat pituitary cell assay which measured basal release of FSH. Using this assay system, the dose of WLG-4-55B which gave inhibition of 50% of FSH release was estimated to be 55 ng (by W. L. Gordon at Houston) and 62 ng (by F. H. de Jong at Rotterdam). The purity of this preparation was estimated to be about 1-3% (w/w) (Waites et al., 1987) . In 1986, it was considered that FSH-stimulating proteins (activins) were the bioactive agents most likely to be present in the extract and to interfer in the pituitary cell assay. However, as reported by Waites et al. (1987) , published work from another group (Vale et al., 1986) had shown that the molar ratio of inhibimactivin which resulted in interference was 10:1, and no activin activity was found when the preparation WLG-4-55B was fractionated by high-performance liquid chromatography.
Distribution into ampoules. In November 1986, 37-9 mg of WLG-4-55B was added to 38 ml of a diluent consisting of acetic acid (1 mmol 1_1) containing 01% purified peptidase-free human plasma albumin (Lister Institute, Elstree, UK), 0-5% trehalose and 1-5 mmol sodium chloride 1" ' at pH 4-5. Glacial acetic acid was added drop by drop to a final concentration of about 400 mmol I"1. The ECBS, 1990) .
Preliminary assessment ofampoule contents. The potencies of the bulk WLG-4-55B and the ampoule contents of 86/690 were estimated in terms of the NIH folliculostatin reference preparation FS RP 119-6-4, ovine testicular lymph protein (oTLP) and of in-house standards of bovine follicular fluid. Rat pituitary cell assays measuring FSH release and cell content were used. The data indicated that most of the activity of the bulk had been retained during the distribution into ampoules.
Although exhibited some protease activity when tested with a chromogenic substrate (Caygill, 1977 In addition, workers at seven laboratories included their own laboratory working standard(s) in their assays. These local standards were derived from rat Sertoli cell conditioned medium, partially purified porcine follicular fluid, ovine follicular fluid and bovine follicular fluid.
Participants and design of the study Ten participants in eight countries took part in the study (Table 2) . Throughout this report, each laboratory is identified by a number from 1 to 10, not related to the order of listing.
There was insufficient material for in vivo studies and the immunoassay phase of the study was deferred until recombinant human inhibin becomes available in sufficient quantity for study as a possible International Standard. Subject to these constraints, participants were asked to carry out their usual in vitro bioassay procedure, to use freshly reconstituted ampoules and to use sufficient replicates at multiple doses to provide data for analysis of variance and assessment of linearity and parallelism. Participants were requested to include in each assay one of each of the samples provided. However, restrictions on the available number of ampoules of some of the preparations together with ai, 1979; Franchimont et ai, 1979; Scott et al., 1980; Miyamoto et al., 1985) , one used female rats (Sasamoto et al., 1987) , one used young (18-20 days old) male rats (Steinberger & Steinberger, 1976) , one had a short-term (1 h preincubation, 4 h incubation with inhibin) culture of whole pituitary glands from rats (Sheth, 1987) (Welschen et al., 1975) ; ovine FSH was measured according to a published method (McNeilly et ai, 1976) .
Each participant contributed data for two independent (i.e. using freshly reconstituted ampoules) in vitro bioassays (except laboratory 6, one assay only, and laboratory 8, a third assay using previously made up samples). In addition, laboratory 2 carried out two further assays based on inhibition of LHRH-stimulated secretion of FSH.
Given the practical constraints of working under sterile conditions, at 37°C, and the need for a specific gaseous phase (5% C02 in air) to maintain the pH of the medium, it was evident that participants followed a sequential addition of doses and preparations rather than a randomized design. Participants who reported assay design information included control wells (no inhibin) and in some cases an internal quality control on each plate.
Statistical analysis
Response data for analysis were derived from immunoassay of FSH and were taken to be either the raw counts (corrected for 'control' counts as appropriate, laboratories 2, 4, 8) or the measured FSH concentration in ng ml"1 (counts not being reported) in laboratories 1, 3, 5, 6, 9 and 10. Variation due to method of calculation was minimized by treating data from all laboratories in as uniform a manner as possible.
All FSH response data were plotted against log dose of inhibin and assessed visually for outliers and conformity to a consistently increasing or decreasing dose-response relationship. Data were then assessed statistically for outliers and homogeneity of variances (using the program scan, Gaines Das & Rice, 1985) . Individual responses that were detected as statistical outliers within the particular dose level and that also increased the variance of the particular group so that they made a significant contribution to the heterogeneity 2 were deleted. Doses 
Variability of estimates
The estimated activity of C, identical to 86/690, expressed as percent relative proportion of the activity of 86/690 is shown in Table 4 and Fig. 1 . This estimate was expected to be 100% independently of assay system since 86/690 and C are known to be identical except for code, but, although the overall mean of 108% (95% confidence limits 91-128%) is consistent with this, individual estimates for the in vitro bioassays vary almost fourfold, ranging from 64 to 235%.
The variability of these estimates has been subdivided into two components, namely intralaboratory interassay variation and interlaboratory variation (Table 5) . Moreover, the deviation of estimates of the relative activity of C in terms of 86/690 from the expected value of 100% provides a direct measure of intra-assay variation (Table 5 Fig. 2 ). There were significant differences among estimates from the remaining laboratories. Omitting laboratories 1 (unexplained excessive intra-assay variation) and 5, the intralaboratory mean square is 006 (similar to that obtained for C); but the interlaboratory mean square is 0-79 (substantially larger than that obtained for C). There is no obvious difference in assay systems to account for the differences.
Five of the laboratories included local standards calibrated in 'units' of which four were specifically identified as derived from bovine follicular fluid. Estimates for these, in terms of units of 86/690 equivalent to 1 'unit' of in house standard, were reasonably consistent with estimates for 87/534 (Table 6 ).
Comparison of 86/690 with ovine rete testis fluid (87/596) and the various human preparations (87/546 and 87/716) For any one of these materials, the estimates (Table 6 , Fig. 2 ) had an intralaboratory variance similar to that obtained for the comparison of C with 86/690, but the interlaboratory variance was larger than that obtained for C (interlaboratory mean squares of some 0-4) and there were significant differences among estimates from the different laboratories. These differences did not appear to be related to the obvious differences among the assay systems (Fig. 2) .
Discussion
All laboratories confirmed the biological activity of the research standard of porcine inhibin, 86/690, which has been used as the reference standard for this collaborative study with its previously adopted potency of 2000 units per ampoule.
The coded duplicate of 86/690, ampoule C, gave an overall mean of 108% of the activity of 86/690 in good agreement with its expected value of 100%, although individual estimates varied bOmitting estimates from laboratory 1. Given the inherent almost four-fold variation for comparisons of identical materials and the apparent influence of assay design on the results of these comparisons, the comparisons of 'unlike' substances, which varied with a three-to sixfold range cannot readily be interpreted. It is certainly likely that the variation observed for comparisons of unlike substances, particularly those which are not highly purified, may be due to the presence of other bioactive entities such as activin (although this seems unlikely as discussed earlier) or of follistatins (Ueno et al., 1987) as well as to differences in assay systems (as discussed by Robertson et al., (1986 Robertson et al., ( , 1990 . However, despite the cautions that need to be considered when interpreting the results of pituitary cell assays, the fact remains that progress on the biological activity of inhibin (and activin and follistatin) and insight into its physiology have depended on such bioassay systems 
